Perceptive Advisors LLC Acquires New Position in X4 Pharmaceuticals, Inc. $XFOR

Perceptive Advisors LLC acquired a new stake in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) in the 4th quarter, Holdings Channel.com reports. The firm acquired 6,314,452 shares of the company’s stock, valued at approximately $25,258,000. Perceptive Advisors LLC owned 0.07% of X4 Pharmaceuticals as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Indivisible Partners acquired a new stake in shares of X4 Pharmaceuticals in the fourth quarter valued at about $40,000. Rhumbline Advisers lifted its stake in shares of X4 Pharmaceuticals by 5.4% in the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after purchasing an additional 9,690 shares during the period. Two Sigma Investments LP acquired a new stake in shares of X4 Pharmaceuticals in the third quarter valued at about $47,000. Squarepoint Ops LLC acquired a new stake in shares of X4 Pharmaceuticals in the fourth quarter valued at about $50,000. Finally, Stifel Financial Corp acquired a new stake in shares of X4 Pharmaceuticals in the fourth quarter valued at about $82,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Stock Performance

Shares of XFOR opened at $4.05 on Thursday. The company has a current ratio of 10.18, a quick ratio of 9.98 and a debt-to-equity ratio of 0.45. The stock has a market cap of $382.00 million, a P/E ratio of -0.89 and a beta of 0.34. The company has a 50-day moving average of $4.08 and a two-hundred day moving average of $3.89. X4 Pharmaceuticals, Inc. has a 12-month low of $1.35 and a 12-month high of $4.83.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. The company had revenue of $2.71 million during the quarter, compared to analysts’ expectations of $3.20 million. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. As a group, research analysts predict that X4 Pharmaceuticals, Inc. will post -0.77 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on XFOR shares. Weiss Ratings cut shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 4th. Wall Street Zen upgraded shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Leerink Partners started coverage on shares of X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 price objective for the company. Finally, Guggenheim assumed coverage on shares of X4 Pharmaceuticals in a research note on Monday, March 9th. They issued a “buy” rating and a $12.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, X4 Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $9.38.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.